GLP-1受体激动剂艾塞那肽治疗对2型糖尿病患者缓解期的影响 研究 定稿.doc

GLP-1受体激动剂艾塞那肽治疗对2型糖尿病患者缓解期的影响 ( 黄艾平* 张弛( 陈丹丹( 赵乃蕊( 李华珠( 杨晓春( 周桂莲( 冯晶*王敏( 吴文宇( 熊璞( 陈晶( 王霞( 湖南省人民医院(湖南省师范大学第一附属医院) 药学部(、内分泌科( （410005） 摘要 目的：研究艾塞那肽治疗对2型糖尿病患者缓解期的影响。方法：选择自2009年11月～2010年10月我院内分泌科收治的57例2型糖尿病患者为研究对象，按照病程、体重指数、空腹餐后C肽、血脂、原有治疗方案一一配对分成艾塞那肽组（n=31）及对照组（n=26）。共治疗3个月，每月随访一次，检测血糖、HbA1C、C肽、胰岛素，治疗前与治疗3月后行72小时动态血糖监测、静脉葡萄糖耐量试验。对两组进行分析比较研究，探讨艾塞那肽治疗对2型糖尿病患者缓解期的影响。结果：1．艾塞那肽治疗3月，16.13%（n=5）的2型糖尿病患者出现缓解期，与对照组相比差异有统计学意义（P 0.05）；2．与治疗前相比，空腹、餐后血糖、HbA1C下降，高血糖及低血糖所占时间比下降，差异有统计学意义（P 0.05）。 结论：艾塞那肽治疗可促进2型糖尿病患者出现缓解期。 关键词：艾塞那肽，2型糖尿病，缓解期，治疗 GLP-1 receptor agonist exenatide treatment on the remission of type 2 diabetes Huangaip( Zhangchi( Chendandan( Zhannairui( Lihuazhu( Yangxiaochun( Zhouguilian( Fenjin(Wangming( Wuwenyu( Xionpo( Chenjin( Wangxia( Hunan Provincial Peoples Hospital（First Affiliated Hospital of Hunan Province Normal）, Department of Pharmacy(, Department of Endocrinology(,(410005) Abstract Objective: Investigate the impact of GLP-1 receptor agonist exenatide on the remission period in type 2 diabetes. Method: 57 patients with type 2 diabetes were divided into Group A, which were given the treatment of exenatide, and Group B, which were controls. The two groups were comparable in duration, body mass index (BMI), fasting and postprandial serum C-peptide, serum lipid and the original treatment. During follow-up, plasma glucose, HbA1c, serum insulin and C-peptide were evaluated every month. After 3 month, continuous glucose monitoring (CGM) and intravenous glucose tolerance test (IVGTT) were performed. Compare the rate of patients who achieved remission in two groups. Results: In type 2 diabetics with the treatment of exenatide, 16.13% (n=5) of them achieved remission, the rate was significantly higher than the control group. Compared with those before treatment, fasting and postprandial blood glucose, HbA1c and the rate of hyperglycemia and hypoglycemia during CGM were significantly lower. Conclusion: Exenatide therapy can promote type 2 diabetes remission